

## Bibliography Report

March 1, 2007–March 31, 2007

Page 1 of 1

---

Barbaric D, Alonzo T, Gerbing R, Meshinchi S, Heerema NA, Barnard DR, Lange B, Woods WG, Arceci R, Smith FO. Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Cancer Group studies CCG-2891 and -2961. *Blood*; 109(6):2314-2321, 2007.

Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars L, Adamson P, Ingle AM, Wright J, Brockman A, Paton M, Blaney S. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group Study. *Clin Cancer Res*; 13(5):1516-1522, 2007.

Kretschmar CS, Kleinberg L, Greenberg M, Burger P, Holmes E, Wharam MD. Preradiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors: a report from the Children's Oncology Group. *Pediatr Blood Cancer*; 48(3):285-291, 2007.

Su Y, Davies SM, Davis M, Lu H, Giller R, Krailo M, Cai Q, Robison L, Shu XO. Expression of LINE-1 p40 protein in pediatric malignant germ cell tumors: a Children's Oncology Group study. *Cancer Lett*; 247(2):204-212, 2007.

Teot LA, Sposto R, Khayat AF, Qualman S, Reaman GH, Parham D. The problems and promise of central pathology review: development of a standardized procedure for the Children's Oncology Group. *Pediatr Dev Pathol*; [Epub ahead of print] 2007.

Weigel BJ, Blaney S, Reid JM, Safgren SL, Bagatell R, Kersey J, Neglia J, Ivy SP, Ingle AM, Whitesell LJ, Gilbertson RJ, Krailo M, Ames MM, Adamson P. A phase I study of 17-allylaminogeldanamycin (17-AAG) in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. *Clin Cancer Res*; 13(6):1789-1793, 2007.